Results

1–9 of 9 results for David S. Boyer

Phentolamine Ophthalmic Solution Rapidly Reverses Pharmacologically Induced Mydriasis in Two Pivotal Phase 3 MIRA Trials
David S. Boyer, MD
Annual Meeting Talks
2022
Phentolamine Ophthalmic Solution Rapidly Reverses Pharmacologically Induced Mydriasis in Two Pivotal Phase 3 MIRA Trials
David S. Boyer, MD
Updates from the Field
2022
Switching to Combination OPT-302 With Aflibercept From Prior Anti-VEGF-A Monotherapy in Eyes With Persistent Diabetic Macula Edema (DME)
David S. Boyer, MD
Annual Meeting Talks
2020
Evaluating Intravitreal ANX007, a Novel C1q Inhibitor, in the Treatment of GA Secondary to AMD: The ARCHER Study
David S. Boyer, MD
Updates from the Field
2021
Safety of Intravitreal Pegcetacoplan in Geographic Atrophy: Results from the Phase 3 DERBY and OAKS Trials
David S. Boyer, MD
Updates from the Field
2021
The Average Patient Does Not Enter Your Office: What Can We Learn About Treating nAMD From Individual Patient Responses
David S. Boyer, MD
Annual Meeting Talks
2019
Effect of Baseline Ocular Characteristics on Vitreomacular Adhesion/Vitreomacular Traction Resolution With Ocriplasmin: ORBIT Study Subanalysis
David S. Boyer, MD
Annual Meeting Talks
2018
Twelve Month Safety and Efficacy Outcomes from a Phase 2 Study of APL-2 in Patients with Geographic Atrophy
David S. Boyer, MD
Updates from the Field
2017
Surveying the Dry AMD Landscape. Is help on the way?
David S. Boyer, MD
Updates from the Field
2019